Northwire Canada EditionThursday, October 15, 2026
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
M&A / Property Routine +

Realbotix Provides Update on Nasdaq Listing

Nasdaq Listing Update Confirms Path to Liquidity

Executive Summary
  • Realbotix Corp. provided an update on its reverse takeover transaction with Onconetix, Inc. (NASDAQ: ONCO).
  • The transaction aims to list Realbotix LLC (commercial robotics/AI subsidiary) on the Nasdaq Capital Market by October 2026.
  • Parent Company will retain a 75–90% ownership stake in the resulting Nasdaq-listed entity upon closing.
  • No new shares will be issued by the Parent Company, and no share consolidation is required for existing shareholders.
  • Realbotix will appoint four out of five directors to the ONCO board at closing.
  • The strategic rationale includes unlocking value in commercial robotics, separating it from direct-to-consumer business, and accessing non-dilutive financing via Nasdaq.
Material Impact
  • Status Update: This news is a follow-up to the February 12, 2026 announcement of the reverse takeover agreement; therefore, it does not contain genuinely new strategic information but confirms progress on an existing deal.
  • Valuation Impact: Listing on Nasdaq Capital Market typically improves liquidity and access to institutional investors compared to TSX Venture, which is a positive structural change for valuation multiples over time.
  • Dilution Concerns: The confirmation that no new shares will be issued by the Parent Company mitigates immediate dilution risk for existing shareholders, preserving their 75–90% interest in the listed entity.
  • Operational Context: This update must be weighed against Q1 2026 financial results released March 9, which showed a 57% year-over-year revenue decline ($353k vs $815k), indicating operational headwinds despite the capital market progress.
  • Risk Mitigation: The deal structure allows Realbotix to maintain control while accessing US capital markets, but execution risk remains regarding regulatory approvals (TSX Venture and ONCO shareholders).
XBOT · Price
Company Overview
  • Company: Realbotix Corp., a TSX Venture listed entity focused on AI-powered humanoid robotics.
  • Flagship Project: Realbotix LLC, a subsidiary specializing in autonomous humanoid robots for healthcare, education, hospitality, and entertainment sectors.
  • Technology: Proprietary AI vision system "Vinci" enabling eye contact maintenance, user recognition, and emotional signal capture; embedded on-device AI models running without cloud reliance.
  • Commercialization: Recent deployments include Ericsson (workforce training/visitor engagement) and The FUTR Corporation (AI agents in physical world).
  • Facilities: Relocating robotics operations to a new Las Vegas corridor facility by late June 2026 to support scaled production.
Read the original news release →

More from Realbotix Corp.